Abstract:OBJECTIVE:To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125. METHODS:Apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes were assessed by flow cytometry. Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20). Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor. Level of serum CA125 of the patients with ovarian cancer was assessed. RESULTS:In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05). The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05). In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances). The apoptosis level and positive rate of Fas expression on peritoneal fluid T lymphocytes from patients with stage III - IV ovarian cancer were significantly higher than those from patients with Krukenberg tumor (P < 0.01). There was a positive correlation between the serum CA125 level and the apoptosis level of peritoneal fluid T cell in the patients with stage I - II ovarian cancer (r = 0.77, P = 0.009). For ovarian cancer, the apoptosis level of peritoneal fluid T lymphocytes from patients with the serum CA125 > 500 KU/L was higher than that from the patients with the serum CA125 < or = 500 KU/L (P = 0.009). CONCLUSIONS:(1) Extraordinarily increased apoptosis of T cells may play an important role in the development of systemic and celiac immunodeficiency in the patients with ovarian cancer. In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.

Preliminary Study of Immunological Characteristics of Human Ovarian-Specific CTLs

In vitro anti-tumor effect of cytotoxicity T lymphocytes activated by dendritic cells loaded with freeze-thaw ovarian carcinoma antigen

Anti-tumor Effect and Its Antigenic Specificity of Cytotoxicity T Lymphocytes Induced by SKOV3 Ovarian Carcinoma Cell Line Freeze-thaw Antigen

Ovarian carcinoma cells inhibit CD 69 expression in CD 8+T cells

Proportion of CD4 CD25 Regulatory T Cell is Increased in the Patients with Ovarian Carcinoma

Cytotoxicity of peripheral blood lymphocyte-mediated by an anti-human ovarian carcinoma-anti-human CD3 bispecific single-chain antibody(BHL-I)in vitro and its mechanisms

Study on the influence factors upon the specificity and sensitivity of CTL killing in vitro

[Study of HLA Molecules and Its Associated Genes Expression in Human Ovarian Cancer Cells].

Study on HLA Class I antigen sssociation with renal cell carcinoma and ovarian cancer

In Vitro Study on Cytotoxicity of T Cells Induced by Dendritic Cells Loaded with 6B11 Anti-Idiotypeminibody to Ovarian Cancer Cell Lines

Ovarian carcinoma cells inhibit ζ chain expression and the secretion of Tc1/Tc2 type cytokines in CD8 + T cells

Study of Apoptosis and Fas Expression of Peritoneal Fluid and Peripheral Blood T Lymphocytes in Patients with Epithelial Ovarian Cancer and Their Relationship with CA125

[Identification of a Novel HLA-A2-restrictive CTL Epitope of an Ovary Cancer-Associated Antigen OVA66].

THE IMMUNOHISTOCHEMICAL STUDY OF DENDRITIC CELL PHENOTYPIC ANTIGENS IN HUMAN OVARIAN EPITHELIAL CARCINOMA

Human Epithelial Ovarian Carcinoma Cell-Derived Cytokines Cooperatively Induce Activated Cd4+Cd25-Cd45ra+Naive T Cells To Express Forkhead Box Protein 3 And Exhibit Suppressive Ability In Vitro

Ovarian Carcinoma Cells Inhibit T Cell Proliferation: Suppression of IL-2 Receptor Β and Γ Expression and Their JAK-STAT Signaling Pathway

Clinical study on immunotherapy of ovarian cancer with tumor infiltrating lymphocytes]

Humoral Immune Responses Against Tumor‐associated Antigen OVA66 Originally Defined by Serological Analysis of Recombinant Cdna Expression Libraries and Its Potentiality in Cellular Immunity

Study on the phenotype and function of CD8+Treg cells induced by ovarian cancer cell

Immunogenicities of Apoptotic Ovarian Cancer Cells Induced by Paclitaxel Combined with Cisplatin

Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody